This site is intended for health professionals only
Sunday 26 May 2019
Share |

Big pharma warns of mass exodus

The Government's decision to renegotiate its drug pricing mechanism with the pharmaceutical industry midway through the current five-year deal has been criticised by the Association of the British Pharmaceutical Industry (ABPI).

The ABPI said the decision could result in pharma firms relocating away from the UK.

The group said while the move may save the NHS up to £1bn from its annual drugs bill, the changes within the industry of a mass move away from the UK would be disastrous for the sector.

Many pharma companies believe that the new pricing policy may hurt their interests if the drug regulators take cheaper generic drug prices as a reference.

While Shire plans to move its corporate HQ to Ireland for tax purposes, AstraZeneca and are thought to have  a similar move under consideration.

Nigel Brooksby, outgoing ABPI president, said: "We are committed to working with the government to retain leadership in the UK, provide value for money, encourage and reward innovation, assist in the uptake of new medicines and help restore industry confidence through predictability, stability and sustainability."

Copyright © PA Business 2008

Association of the British Pharmaceutical Industry

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher